- Conditions
- Healthy, Food-drug Interaction
- Interventions
- Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
- Interventions
- Placebo, IMG-007
- Drug
- Lead sponsor
- Inmagene LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Northridge, California • Valencia, California • Miami, Florida + 6 more
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic
- Interventions
- Eltrekibart, Mirikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
- Conditions
- End Stage Renal Disease, Antibody Mediated Rejection
- Interventions
- Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
- Drug · Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Ulcerative Colitis
- Interventions
- HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day
- Drug
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Agawam, Massachusetts
- Conditions
- Hepatic Impairment
- Interventions
- AG-120 (Ivosidenib)
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Lakewood, Colorado • Minneapolis, Minnesota
- Conditions
- Renal Impairment
- Interventions
- GBT440
- Drug
- Lead sponsor
- Global Blood Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Esophagogastric Cancer, Moderate to Severe Dysphagia
- Interventions
- WST 11-mediated VTP therapy
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Psoriasis
- Interventions
- BMS-986322, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Encino, California • Fountain Valley, California + 15 more
- Conditions
- Renal Insufficiency
- Interventions
- Dalfampridine-ER
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Anaheim, California • South Miami, Florida
- Conditions
- Renal Impairment, Healthy Volunteers
- Interventions
- TAK-279
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Chicago, Illinois
- Conditions
- Hepatic Insufficiency
- Interventions
- Alisporivir
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease
- Interventions
- Corticosteroid
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- aldesleukin
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Plaque Psoriasis
- Interventions
- ASC50 tablets or matching placebo
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Asthma
- Interventions
- L-arginine, Placebo
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Ulcerative Colitis
- Interventions
- CurQD, Placebo, Vedolizumab
- Drug
- Lead sponsor
- Ryan C Ungaro
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy, Renal Impairment
- Interventions
- quinine sulfate
- Drug
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Miami Gardens, Florida
- Conditions
- Hidradenitis Suppurativa (Acne Inversa)
- Interventions
- CJM112, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Ormond Beach, Florida • Tampa, Florida + 6 more
- Conditions
- Opioid Use Disorder
- Interventions
- Drug Cue, Money, Withdrawal, Remifentanil
- Behavioral · Drug
- Lead sponsor
- Joshua A. Lile, Ph.D.
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more
- Conditions
- Crohn's Disease
- Interventions
- Etrasimod, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 192
- States / cities
- Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more
- Conditions
- Chronic Low-back Pain
- Interventions
- Algorithmically informed randomization (taking into account phenotypes), Physical Therapy (PT) and Exercise, Cognitive-Behavioral Therapy for Pain (PRISM-CBT), mHealth Acupressure Self-Management:, Duloxetine
- Device · Behavioral · Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Gulf War Illness
- Interventions
- plain crystalline niacin, exercise, sauna
- Drug
- Lead sponsor
- University at Albany
- Other
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Annapolis, Maryland